• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Wedbush reiterated coverage on Codiak BioSciences with a new price target

    2/22/22 8:48:06 AM ET
    $CDAK
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CDAK alert in real time by email
    Wedbush reiterated coverage of Codiak BioSciences with a rating of Outperform and set a new price target of $24.00 from $34.00 previously
    Get the next $CDAK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CDAK

    DatePrice TargetRatingAnalyst
    2/22/2022$34.00 → $24.00Outperform
    Wedbush
    2/11/2022$19.00Buy
    Goldman Sachs
    More analyst ratings

    $CDAK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Codiak BioSciences to Pursue Asset Sale through Voluntary Chapter 11 Process

      CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that the Company has voluntarily filed for protection under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware and will seek to pursue a sale process for its assets which is intended to maximize the value of the Company. The Company began a marketing process ahead of the Chapter 11 filing to determine the level of market interest and is in ongoing discussions with several parties. The Company expects

      3/27/23 7:00:00 AM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • Codiak BioSciences to Participate 5th Annual Evercore ISI HealthCONx Conference

      CAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that management will be participating in the 5th Annual Evercore ISI HealthCONx Conference, a virtual conference. Codiak's Chief Executive Officer, Douglas E. Williams, Ph.D., will participate in a fireside chat on Wednesday, November 30 at 8:00 am ET and the Company will also be hosting one-on-one meetings at the conference. A live webcast of the fireside chat will be available on the Investors & Media section of the Codiak website at www.codiakbio.com. A

      11/28/22 1:00:00 PM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • Codiak Presents Preclinical Data on exoASO™-STAT6 and exoASO™-C/EBPβ Programs at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

      – exoASO-STAT6 demonstrated durable pharmacokinetic/pharmacodynamic profile in preclinical models; biomarkers with clinical translational potential identified, providing a rationale for selecting cancer subtypes for treatment with exoASO-STAT6 – – Systemically administered exoASO-C/EBPβ demonstrated extra-hepatic delivery and potent systemic anti-tumor activity across multiple myeloid-derived suppressor cell (MDSC) rich tumor models – – A Phase 1 clinical trial of exoASO-STAT6 in patients with advanced hepatocellular carcinoma (HCC), is ongoing; initial data expected in the first half of 2023 – CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a

      11/10/22 9:00:00 AM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care

    $CDAK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Howze Yalonda

      4 - Codiak BioSciences, Inc. (0001659352) (Issuer)

      3/30/23 6:01:07 PM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Sathyanarayanan Sriram

      4 - Codiak BioSciences, Inc. (0001659352) (Issuer)

      3/30/23 5:19:21 PM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Konstantinov Konstantin

      4 - Codiak BioSciences, Inc. (0001659352) (Issuer)

      3/30/23 5:13:35 PM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care